Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

  • STATUS
    Recruiting
  • End date
    May 14, 2023
  • participants needed
    250
  • sponsor
    Pfizer
Updated on 5 May 2022
replacement therapy
gene therapy
Factor VIII
hemophilia
severe haemophilia a
antihemophilic factor
christmas disease

Summary

To establish a minimum of 6 months of prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study.

To establish a minimum of 6 months of prospective efficacy data of current FVIII prophylaxis replacement therapy in the usual care setting of hemophilia A subjects, who are negative for nAb to SB-525 capsid (AAV6), prior to the Phase 3 gene therapy study.

The enrollment for hemophilia A participants is completed. At this time participants are only being enrolled for hemophilia B cohort.

Description

AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF CURRENT FACTOR IX (FIX) OR FACTOR VIII (FVIII) PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES TO ADENO-ASSOCIATED VIRUS VECTOR-SPARK100 (BENEGENE-1) AND MODERATELY SEVERE TO SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES TO ADENO-ASSOCIATED VIRUS VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC PHASE 3 GENE THERAPY STUDIES

Details
Condition Hemophilia B, Hemophilia A
Treatment Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy
Clinical Study IdentifierNCT03587116
SponsorPfizer
Last Modified on5 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Hemophilia B Population
Evidence of a personally signed and dated informed consent document indicating that the participant or his legally authorized representative has been informed of all pertinent aspects of the study
Willing and able to comply with scheduled visits, FIX prophylaxis treatment plan, laboratory tests and other study procedures
Males ≥ 18 and <65 years of age with moderately severe to severe hemophilia B and documented FIX activity (≤2%) prior to baseline visit
Previous experience with FIX therapy (≥50 documented exposure days to a FIX protein product such as recombinant, plasma-derived or extended half-life FIX product)
Subjects on FIX prophylaxis replacement therapy (recombinant, plasma-derived or extended half-life FIX product) must have the intention to remain on FIX prophylaxis replacement therapy for the duration of the study
No known hypersensitivity to FIX replacement product
No history of FIX inhibitor (clinical or laboratory-based assessment) defined as a titer
6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda inhibitor titer greater than the upper limit of normal for the laboratory performing the assay. Clinically, no signs or symptoms of decreased response to FIX administration. Subjects will not be required to undergo diagnostic evaluation of inhibitor status to participate in the study
Hemophilia A Population
Evidence of a personally signed and dated informed consent document indicating that the participant or his legally authorized representative has been informed of all pertinent aspects of the study
Willing and able to comply with scheduled visits, FVIII prophylaxis treatment plan, laboratory tests and other study procedures
Males ≥18 and <65 years of age with moderately severe to severe hemophilia A and documented FVIII activity (≤1%) prior to baseline visit
Previous experience with FVIII therapy (≥150 documented exposure days to a FVIII protein product such as recombinant, plasma-derived or extended half-life FVIII product)
Subjects on FVIII prophylaxis replacement therapy (recombinant, plasma-derived or extended half-life FVIII product) must have the intention to remain on FVIII prophylaxis replacement therapy for the duration of the study
No known hypersensitivity to FVIII replacement product
No history of FVIII inhibitor (clinical or laboratory-based assessment) defined as a titer ≥0.6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda inhibitor titer greater than the upper limit of normal for the laboratory performing the assay. Clinically, no signs or symptoms of decreased response to FVIII administration. Subjects will not be required to undergo diagnostic evaluation of inhibitor status to participate in the study

Exclusion Criteria

Anti-AAV-Spark100 neutralizing antibody titer above or equal to 1:1 performed by a central laboratory during screening in hemophilia B subjects or Anti- SB-525 capsid (AAV6) neutralizing antibody titer (above or equal to the lowest detectable titer) performed by a central laboratory during screening in hemophilia A subjects
Lack of patient compliance with documentation of bleeds and/or prophylaxis replacement therapy administration
If there is no documentation regarding hepatitis status, as defined below, within the last 12 months prior to screening for hepatitis B and 6 months prior to screening for hepatitis C, then subjects will be required to have the following hepatitis testing performed at screening
Hepatitis B screening (acute and chronic)
HBsAg (also referred to as Hepatitis B surface antigen), HBV-DNA viral assay
(also referred to as a nucleic acid test for Hepatitis B virus DNA), and Anti-
HBc (also referred to as Total Hepatitis B core antibody)
A subject is not eligible if either HbsAg is positive or HBV-DNA is positive/detectable
Anti-HBc must be obtained in all subjects for determination of whether the subject had prior hepatitis B. If the anti-HBc is positive and both HBsAg and HBV DNA are negative this would be consistent with a prior infection and the subject would be eligible for the study. Anti-HBc must be obtained in all subjects to discriminate between those with no prior hepatitis B and those with prior infection in the event of reactivation. FDA has noted reactivation of hepatitis B virus exists
One documented negative HBV-DNA viral load is sufficient to assess eligibility. A subject who is currently undergoing anti-viral therapy for hepatitis B is not eligible
A subject who is currently undergoing anti-viral therapy for chronic hepatitis C is not eligible
Hepatitis C (acute or chronic)
Subjects treated with anti-viral therapy for chronic hepatitis C, must have completed anti-viral therapy at least 6 months prior to screening and have a negative HCV-RNA at least 6 months prior to screening
All subjects (who are not currently undergoing anti-viral therapy for chronic hepatitis C) must have a single HCV-RNA load assay (also referred to as a nucleic acid test [NAT] for HCV RNA) obtained during the 6 months preceding screening. This includes subjects with prior known chronic hepatitis C who have completed treatment with anti-viral therapy
Portal hypertension; or
A subject is not eligible if his HCV-RNA load assay result is positive/detectable
Splenomegaly; or
Currently on antiviral therapy for hepatitis B or C
Hepatic encephalopathy
A subject is not eligible if any of the following pre-existing diagnoses, which are indicative of significant underlying liver disease, are present in the medical record
All subjects who do not have the listed pre-existing diagnoses above must have the
following assessments performed within the last 12 months prior to screening and if
not will need to be tested for liver fibrosis status at screening
FibroScan, with a score >8.3 kPa units
Measurement of serum albumin. A subject is not eligible if the serum albumin
FibroTest/FibroSURE with a result >0.48; or
level is below the testing laboratory's lower limit of normal; and
One of the following diagnostic tests for liver fibrosis. The following results
are indicative of fibrosis and exclude the subject from participation
AST-to-Platelet Ratio Index (APRI) >1
Please note, if a subject has a known history of Gilbert's syndrome, a
FibroTest cannot be used for fibrosis testing
Documented serological evidence of human immunodeficiency virus HIV-1 or HIV-2 with
Cluster of Differentiation 4 positive (CD4+) cell count ≤200 mm3 within the last 12
months prior to screening. Subjects who are HIV positive and stable, have an adequate
CD4 count (>200/mm3) and undetectable viral load (<50 gc/mL) documented within the
preceding 12 months, and are on an antiretroviral drug regimen are eligible to enroll
Subjects who have not been tested within the prior 12 months of screening will need to
be tested for HIV status at screening
History of chronic infection or other chronic disease that the investigator deems an
unacceptable risk. Any patient with a history of thrombotic events including but not
limited to stroke or myocardial infarction
Any concurrent clinically significant major disease or condition that the investigator
deems unsuitable for participation or other acute or chronic medical or psychiatric
condition including recent (within the past year) or active suicidal ideation or
behavior or laboratory abnormality that may increase the risk associated with study
participation or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the subject inappropriate for entry into this
study
Participation in other studies if involving administration of investigational
product(s) within the last 3 months prior to study entry and/or during study
participation or in a previous gene therapy clinical study within the last 12 months
prior to screening
• Participants already enrolled in this lead-in study (C0371004) may be allowed to
participate in the screening and baseline periods of either C0371002 or C3731003
protocols prior to their completion of the end of study visit in this lead-in study
Any subject who previously received fidanacogene elaparvovec (SPK-9001) (hemophilia B)
or SB-525 (hemophilia A) or any AAV gene-based therapy
Any subject with a planned surgical procedure requiring FIX (hemophilia B) or FVIII
(hemophilia A) surgical prophylactic factor treatment in the next 24 months
Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note